The Role of P2X7 Receptor in Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease characterized by a progressive cognitive decline associated with global brain damage. Initially, intracellular paired helical filaments composed by hyperphosphorylated tau and extracellular deposits of amyloid-β (Aβ) were postulated as the causing factors of the synaptic dysfunction, neuroinflammation, oxidative stress, and neuronal death, detected in AD patients. Therefore, the vast majority of clinical trials were focused on targeting Aβ and tau directly, but no effective treatment has been reported so far. Consequently, only palliative treatments are currently available for AD patients. Over recent years, several studies have suggested the involvement of the purinergic receptor P2X7 (P2X7R), a plasma membrane ionotropic ATP-gated receptor, in the AD brain pathology. In this line, altered expression levels and function of P2X7R were found both in AD patients and AD mouse models. Consequently, genetic depletion or pharmacological inhibition of P2X7R ameliorated the hallmarks and symptoms of different AD mouse models. In this review, we provide an overview of the current knowledge about the role of the P2X7R in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Complement and microglia mediate early synapse loss in Alzheimer mouse models
Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., et al. (2016) · Science · doi:10.1126/science.aad8373 · Cited by 3,343 · cited 1×
“Others postulate that microglial cells activated by Aβ are responsible for assaulting the synapses (Hong et al., 2016).”
BackgroundAlzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Krasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.008 · Cited by 2,979
NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898 · cited 2×
“Furthermore, the NLRP3 inflammasome deficiency promoted the switch of microglial cells to M2 state, resulting in decreased deposition of Aβ in APP/PS1 mice (Heneka et al., 2013).”
Background2019 Alzheimer’s disease facts and figures.
Alzheimer's Association (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.010 · Cited by 2,461
Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.010 · Cited by 2,208
Gut microbiome alterations in Alzheimer’s disease
Vogt, N. M., Kerby, R. L., Dill-McFarland, K. A., Harding, S. J., Merluzzi, A. P., Johnson, S. C., Carlsson, C. M., Asthana, S., Zetterberg, H., Blennow, K., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13601-y · Cited by 2,137
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856 · cited 1×
“control of platelet-derived growth factor subunit B (PDGFB) promoter (Mucke et al., 2000).”
BackgroundThe Role of Oxidative Stress in Parkinson's Disease
Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845
The Cytolytic P 2Z Receptor for Extracellular ATP Identified as a P 2X Receptor (P2X 7 )
Surprenant, A., Rassendren, F., Kawashima, E., North, R. A., & Buell, G. (1996) · Science · doi:10.1126/science.272.5262.735 · Cited by 1,739
TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease Model
Wang, Y., Cella, M., Mallinson, K., Ulrich, J. D., Young, K. L., Robinette, M. L., Gilfillan, S., Krishnan, G. M., Sudhakar, S., Zinselmeyer, B. H., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.049 · Cited by 1,736
Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575 · cited 1×
“APP/PS1 mice express a chimeric mouse/human APP and human PSN1, with the deletion of exon 9 found in eFAD patients, under the mouse prion protein promoter (APP/PSN1/P2X7−/−) (Jankowsky et al., 2004).”
BackgroundA polarizing question: do M1 and M2 microglia exist?
Ransohoff, R. M. (2016) · Nature Neuroscience · doi:10.1038/nn.4338 · Cited by 1,573
NLRP3 inflammasome activation drives tau pathology
Ising, C., Venegas, C., Zhang, S., Scheiblich, H., Schmidt, S. V., Vieira-Saecker, A., Schwartz, S., Albasset, S., McManus, R. M., Tejera, D., et al. (2019) · Nature · doi:10.1038/s41586-019-1769-z · Cited by 1,487
Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration
Pétrilli, V, Papin, S., Dostert, C., Mayor, A., Martinon, F., & Tschopp, J. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402195 · Cited by 1,445
NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux
He, Y., Zeng, M. Y., Yang, D., Motro, B., & Núñez, G. (2016) · Nature · doi:10.1038/nature16959 · Cited by 1,295 · cited 2×
“Afterward, the inflammasome recruits the apoptosis-associated speck-like protein (ASC) and the procaspase-1 (another apoptosis-related protein), leading to the secretion of IL1β and IL18 (Petrilli et al., 2007; He et al., 2016).”
BackgroundRole of pro-inflammatory cytokines released from microglia in Alzheimer's disease.
(2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.03.49 · Cited by 1,288
Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells
Israel, M. A., Yuan, S. H., Bardy, C., Reyna, S. M., Mu, Y., Herrera, C., Hefferan, M. P., Van Gorp, S., Nazor, K. L., Boscolo, F. S., et al. (2012) · Nature · doi:10.1038/nature10821 · Cited by 1,253
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224 · cited 1×
“One of those was focused on developing specific monoclonal antibodies against Aβ, both soluble and fibrillar forms (Doody et al., 2013; Salloway et al., 2014; Selkoe, 2019) or try to induce an active immunization.”
BackgroundA three-dimensional human neural cell culture model of Alzheimer’s disease
Choi, S. H., Kim, Y. H., Hebisch, M., Sliwinski, C., Lee, S., D’Avanzo, C., Chen, H., Hooli, B., Asselin, C., Muffat, J., et al. (2014) · Nature · doi:10.1038/nature13800 · Cited by 1,195
CpG islands as gene markers in the human genome
Larsen, F., Gundersen, G., Lopez, R., & Prydz, H. (1992) · Genomics · doi:10.1016/0888-7543(92)90024-m · Cited by 922
Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study
Hanseeuw, B. J., Betensky, R. A., Jacobs, H. I. L., Schultz, A. P., Sepulcre, J., Becker, J. A., Cosio, D. M. O., Farrell, M., Quiroz, Y. T., Mormino, E. C., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1424 · Cited by 865
The Gut Microbiota and Alzheimer’s Disease
Jiang, C., Li, G., Huang, P., Liu, Z., & Zhao, B. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161141 · Cited by 852
Koffie, R. M., Meyer-Luehmann, M., Hashimoto, T., Adams, K. W., Mielke, M. L., Garcia-Alloza, M., Micheva, K. D., Smith, S. J., Kim, M. L., Lee, V. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811698106 · Cited by 850 · cited 1×
“This fact was caused by the interaction of the soluble Aβ peptide oligomers coming from the surrounding plaques with these synaptic contacts (Koffie et al., 2009).”
BackgroundNeuropathology of Alzheimer's Disease
Perl, D. P. (2010) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20157 · Cited by 825 · cited 1×
“Typical hallmarks of AD are extracellular senile plaques and intracellular neurofibrillary tangles (NFTs) (Gahtan and Overmier, 1999; Selkoe, 2001; Avila, 2006; Perl, 2010).”
BackgroundBridel, C., van Wieringen, W. N., Zetterberg, H., Tijms, B. M., Teunissen, C. E., and the NFL Group, Alvarez-Cermeño, J. C., Andreasson, U., Axelsson, M., Bäckström, D. C., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1534 · Cited by 764
Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease
Egan, M. F., Kost, J., Tariot, P. N., Aisen, P. S., Cummings, J. L., Vellas, B., Sur, C., Mukai, Y., Voss, T., Furtek, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1706441 · Cited by 685
Gordon, B. A., Blazey, T. M., Su, Y., Hari-Raj, A., Dincer, A., Flores, S., Christensen, J., McDade, E., Wang, G., Xiong, C., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30028-0 · Cited by 602
Um, J. W., Kaufman, A. C., Kostylev, M., Heiss, J. K., Stagi, M., Takahashi, H., Kerrisk, M. E., Vortmeyer, A., Wisniewski, T., Koleske, A. J., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.06.036 · Cited by 572
Dempsey, C., Rubio Araiz, A., Bryson, K. J., Finucane, O., Larkin, C., Mills, E. L., Robertson, A. A. B., Cooper, M. A., O'Neill, L. A. J., & Lynch, M. A. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.12.014 · Cited by 571 · cited 1×
“Supporting this concept, the NLRP3 inflammasome inhibitor, MCC950, stimulates Aβ phagocytosis in vitro and reduces the number of senile hippocampal plaques in APP/PS1 mice, causing an improvement in their cognitive function (Dempsey et al., 2017).”
BackgroundVermunt, L., Sikkes, S. A. M., van den Hout, A., Handels, R., Bos, I., van der Flier, W. M., Kern, S., Ousset, P., Maruff, P., Skoog, I., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.04.001 · Cited by 570
Walker, D. G., & Lue, L.-F. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0139-9 · Cited by 562
Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.
Wischik, C. M., Edwards, P. C., Lai, R. Y., Roth, M., & Harrington, C. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.11213 · Cited by 547
Randomized trial of verubecestat for prodromal Alzheimer's disease
Egan, M. F., Kost, J., Voss, T., Mukai, Y., Aisen, P. S., Cummings, J. L., Tariot, P. N., Vellas, B., van Dyck, C. H., Boada, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812840 · Cited by 545
Parvathenani, L. K., Tertyshnikova, S., Greco, C. R., Roberts, S. B., Robertson, B., & Posmantur, R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209478200 · Cited by 488
Morris, J. C., Roe, C. M., Grant, E. A., Head, D., Storandt, M., Goate, A. M., Fagan, A. M., Holtzman, D. M., & Mintun, M. A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.269 · Cited by 476
A randomized controlled trial of prednisone in Alzheimer’s disease
Aisen, P. S., Davis, K. L., Berg, J. D., Schafer, K., Campbell, K., Thomas, R. G., Weiner, M. F., Farlow, M. R., Sano, M., Grundman, M., et al. (2000) · Neurology · doi:10.1212/wnl.54.3.588 · Cited by 464
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
Feldman, H. H., Doody, R. S., Kivipelto, M., Sparks, D. L., Waters, D. D., Jones, R. W., Schwam, E., Schindler, R., Hey-Hadavi, J., DeMicco, D. A., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d6476a · Cited by 438 · cited 1×
“Since some studies have shown increased levels of cholesterol promoting the production of Aβ, other clinical trials used statins likes hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors as cholesterol-lowering agents (Carlsson et al., 2008; Feldman et al., 2010).”
ResultLongitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease
Fagan, A. M., Xiong, C., Jasielec, M. S., Bateman, R. J., Goate, A. M., Benzinger, T. L. S., Ghetti, B., Martins, R. N., Masters, C. L., Mayeux, R., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007901 · Cited by 434 · cited 1×
“Preceding the onset of cognitive impairment, following the initial Aβ accumulation, a sequential tau accumulation can be observed (Morris et al., 2009; Bateman et al., 2012; Fagan et al., 2014; Gordon et al., 2018; Hanseeuw et al., 2019).”
BackgroundDissecting phenotypic traits linked to human resilience to Alzheimer’s pathology
Perez-Nievas, B. G., Stein, T. D., Tai, H.-C., Dols-Icardo, O., Scotton, T. C., Barroeta-Espar, I., Fernandez-Carballo, L., de Munain, E. L., Perez, J., Marquie, M., et al. (2013) · Brain · doi:10.1093/brain/awt171 · Cited by 387
NLRP3 inflammasome is expressed and functional in mouse brain microglia but not in astrocytes
Gustin, A., Kirchmeyer, M., Koncina, E., Felten, P., Losciuto, S., Heurtaux, T., Tardivel, A., Heuschling, P., & Dostert, C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130624 · Cited by 369 · cited 1×
“Since pretreatment of cultured microglial cells with potassium chloride (KCl), avoided microglial NRLP3 activation (Gustin et al., 2015), it is reasonable to postulate that efflux of K induced by P2X7R activation is the mechanism by which P2X7R promotes NRLP3 activation in microglial cells.”
BackgroundDNA methylation represses transcription in vivo
Siegfried, Z., Eden, S., Mendelsohn, M., Feng, X., Tsuberi, B.-Z., & Cedar, H. (1999) · Nature Genetics · doi:10.1038/9727 · Cited by 354
The identity and function of microglia in neurodegeneration
Song, W. M., & Colonna, M. (2018) · Nature Immunology · doi:10.1038/s41590-018-0212-1 · Cited by 308 · cited 2×
“At this regard, a recent genome-wide transcriptome analysis of microglia from models of different neurodegenerative disease has allowed to identify a new disease-associated microglia (DAM) phenotype (Krasemann et al., 2017; Song and Colonna, 2018).”
BackgroundNiemi, K., Teirilä, L., Lappalainen, J., Rajamäki, K., Baumann, M. H., Öörni, K., Wolff, H., Kovanen, P. T., Matikainen, S., & Eklund, K. K. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002843 · Cited by 298
Activation of Microglia by Amyloid β Requires P2X7 Receptor Expression
Sanz, J. M., Chiozzi, P., Ferrari, D., Colaianna, M., Idzko, M., Falzoni, S., Fellin, R., Trabace, L., & Di Virgilio, F. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803612 · Cited by 293 · cited 5×
“…release (Sperlagh et al., 2002; Miras-Portugal et al., 2003; Leon et al., 2008), microglial activation, migration, and proliferation (Sanz et al., 2009; Rigato et al., 2012; Martinez-Frailes et al., 2019), glial and Frontiers in Molecular Neuroscience | www.frontiersin.org 3 June…”
BackgroundInfluentialMcLarnon, J. G., Ryu, J. K., Walker, D. G., & Choi, H. B. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000240470.97295.d3 · Cited by 281
Wischik, C. M., Staff, R. T., Wischik, D. J., Bentham, P., Murray, A. D., Storey, J. M. D., Kook, K. A., & Harrington, C. R. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142874 · Cited by 269
Involvement of P2X7 receptors in the regulation of neurotransmitter release in the rat hippocampus
Sperlágh, B., Köfalvi, A., Deuchars, J., Atkinson, L., J. Milligan, C., Buckley, N. J., & Vizi, E. S. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00920.x · Cited by 264
Theunis, C., Crespo-Biel, N., Gafner, V., Pihlgren, M., López-Deber, M. P., Reis, P., Hickman, D. T., Adolfsson, O., Chuard, N., Ndao, D. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072301 · Cited by 259
Usenovic, M., Niroomand, S., Drolet, R. E., Yao, L., Gaspar, R. C., Hatcher, N. G., Schachter, J., Renger, J. J., & Parmentier-Batteur, S. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.1523-15.2015 · Cited by 245
Yuskaitis, C. J., & Jope, R. S. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2008.10.014 · Cited by 240
Lanz, T. A., Carter, D. B., & Merchant, K. M. (2003) · Neurobiology of Disease · doi:10.1016/s0969-9961(03)00079-2 · Cited by 227
Ochalek, A., Mihalik, B., Avci, H. X., Chandrasekaran, A., Téglási, A., Bock, I., Giudice, M. L., Táncos, Z., Molnár, K., László, L., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0317-z · Cited by 225 · cited 1×
“For example, AD patient-derived iPSCs are being used by many research groups (Israel et al., 2012; Kondo et al., 2017; Ochalek et al., 2017; Sullivan and Young-Pearse, 2017; Arber et al., 2019; Chang et al., 2019).”
BackgroundSelf-citationThe P2X7 receptor directly interacts with the NLRP3 inflammasome scaffold protein
Franceschini, A., Capece, M., Chiozzi, P., Falzoni, S., Sanz, J. M., Sarti, A. C., Bonora, M., Pinton, P., & Di Virgilio, F. (2015) · The FASEB Journal · doi:10.1096/fj.14-268714 · Cited by 225
Ling, Y., Morgan, K., & Kalsheker, N. (2003) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(03)00133-x · Cited by 224
Kondo, T., Imamura, K., Funayama, M., Tsukita, K., Miyake, M., Ohta, A., Woltjen, K., Nakagawa, M., Asada, T., Arai, T., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.109 · Cited by 221
Meilandt, W. J., Ngu, H., Gogineni, A., Lalehzadeh, G., Lee, S.-H., Srinivasan, K., Imperio, J., Wu, T., Weber, M., Kruse, A. J., et al. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.1871-19.2019 · Cited by 210 · cited 1×
“Interestingly, recent studies have postulated that this protein plays a central role in the onset and the development of AD because microglia surround and enclose neuritic plaques in a TREM2-dependent manner (Wang Y. et al., 2015; Meilandt et al., 2020).”
BackgroundAlzheimer disease and aducanumab: adjusting our approach
Selkoe, D. J. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0205-1 · Cited by 208 · cited 1×
“One of those was focused on developing specific monoclonal antibodies against Aβ, both soluble and fibrillar forms (Doody et al., 2013; Salloway et al., 2014; Selkoe, 2019) or try to induce an active immunization.”
BackgroundPreliminary Results of a Trial of Atabecestat in Preclinical Alzheimer’s Disease
Henley, D., Raghavan, N., Sperling, R., Aisen, P., Raman, R., & Romano, G. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1813435 · Cited by 197 · cited 1×
“Other strategies have attempted to reduce brain Aβ burden designing new potent secretase inhibitors, both against γ-secretase or BACE1 inhibitors (Egan et al., 2018, 2019; Henley et al., 2019; Lopez Lopez et al., 2019).”
BackgroundIntersection of pathological tau and microglia at the synapse
Vogels, T., Murgoci, A.-N., & Hromádka, T. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0754-y · Cited by 197
New role of P2X7 receptor in an Alzheimer’s disease mouse model
Martin, E., Amar, M., Dalle, C., Youssef, I., Boucher, C., Le Duigou, C., Brückner, M., Prigent, A., Sazdovitch, V., Halle, A., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0108-3 · Cited by 187
Anti‐tau antibody reduces insoluble tau and decreases brain atrophy
Yanamandra, K., Jiang, H., Mahan, T. E., Maloney, S. E., Wozniak, D. F., Diamond, M. I., & Holtzman, D. M. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.176 · Cited by 185
Neuronal P2X7 Receptors Revisited: Do They Really Exist?
Illes, P., Khan, T. M., & Rubini, P. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.3103-16.2017 · Cited by 179
Choi, H. B., Ryu, J. K., Kim, S. U., & McLarnon, J. G. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.5417-06.2007 · Cited by 173
Zhang, D., Pekkanen-Mattila, M., Shahsavani, M., Falk, A., Teixeira, A. I., & Herland, A. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.028 · Cited by 171
Arber, C., Toombs, J., Lovejoy, C., Ryan, N. S., Paterson, R. W., Willumsen, N., Gkanatsiou, E., Portelius, E., Blennow, K., Heslegrave, A., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0410-8 · Cited by 148
Significance of P2X7 Receptor Variants to Human Health and Disease
Sluyter, R., & Stokes, L. (2011) · Recent Patents on DNA & Gene Sequences · doi:10.2174/187221511794839219 · Cited by 147
Block of purinergic P2X7 receptor is neuroprotective in an animal model of Alzheimer's disease
Ryu, J. K., & McLarnon, J. G. (2008) · NeuroReport · doi:10.1097/wnr.0b013e3283179333 · Cited by 134 · cited 5×
“In agreement with this, it has been reported that pharmacological blockade or knocking out the P2X7R in different AD mouse models have positive effects by reducing neuroinflammation (Ryu and McLarnon, 2008; Chen et al., 2018; Martin et al., 2019).”
BackgroundInfluentialP2X7 Receptor Signaling in Stress and Depression
Ribeiro, D. E., Roncalho, A. L., Glaser, T., Ulrich, H., Wegener, G., & Joca, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112778 · Cited by 129
Lee, S.-H., Le Pichon, C. E., Adolfsson, O., Gafner, V., Pihlgren, M., Lin, H., Solanoy, H., Brendza, R., Ngu, H., Foreman, O., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.099 · Cited by 125
Lopez Lopez, C., Tariot, P. N., Caputo, A., Langbaum, J. B., Liu, F., Riviere, M., Langlois, C., Rouzade‐Dominguez, M., Zalesak, M., Hendrix, S., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.02.005 · Cited by 116
Transcription factor Sp1 dysregulation in Alzheimer's disease
Citron, B. A., Dennis, J. S., Zeitlin, R. S., & Echeverria, V. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21695 · Cited by 116
De Simone, R., Niturad, C. E., De Nuccio, C., Ajmone‐Cat, M. A., Visentin, S., & Minghetti, L. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06937.x · Cited by 104
Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease
Lowe, V. J., Lundt, E. S., Albertson, S. M., Przybelski, S. A., Senjem, M. L., Parisi, J. E., Kantarci, K., Boeve, B., Jones, D. T., Knopman, D., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.03.016 · Cited by 90
Martínez-Frailes, C., Di Lauro, C., Bianchi, C., de Diego-García, L., Sebastián-Serrano, Á., Boscá, L., & Díaz-Hernández, M. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00143 · Cited by 83
Self-citationLeón, D., Sánchez-Nogueiro, J., Marín-García, P., & Miras-Portugal, M. T. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2007.12.004 · Cited by 53
Induced pluripotent stem cells as a discovery tool for Alzheimer׳s disease
Sullivan, S. E., & Young-Pearse, T. L. (2017) · Brain Research · doi:10.1016/j.brainres.2015.10.005 · Cited by 50 · cited 1×
“For example, AD patient-derived iPSCs are being used by many research groups (Israel et al., 2012; Kondo et al., 2017; Ochalek et al., 2017; Sullivan and Young-Pearse, 2017; Arber et al., 2019; Chang et al., 2019).”
BackgroundDarmellah, A., Rayah, A., Auger, R., Cuif, M.-H., Prigent, M., Arpin, M., Alcover, A., Delarasse, C., & Kanellopoulos, J. M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.400010 · Cited by 38
Cited by
Greve, H. J., Dunbar, A. L., Lombo, C. G., Ahmed, C., Thang, M., Messenger, E. J., Mumaw, C. L., Johnson, J. A., Kodavanti, U. P., Oblak, A. L., et al. (2023) · Brain · doi:10.1093/brain/awac113 · Cited by 82
Inflamed brain: Targeting immune changes and inflammation for treatment of depression
Sakamoto, S., Zhu, X., Hasegawa, Y., Karma, S., Obayashi, M., Alway, E., & Kamiya, A. (2021) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13286 · Cited by 51
Molecular mechanisms of Alzheimer’s disease: From therapeutic targets to promising drugs
Alan, E., Kerry, Z., & Sevin, G. (2023) · Fundamental & Clinical Pharmacology · doi:10.1111/fcp.12861 · Cited by 17
“Therefore, it is suggested that P2X7R that is upregulated in AD directly contributes to neurodegeneration.(227) P2X7R antagonists and P2X7R deficiency not only reduce the amyloid burden but also increase nonamyloidogenic APP processing in animal AD models.”
BackgroundNon-invasive in vivo imaging of brain and retinal microglia in neurodegenerative diseases
Etebar, F., Harkin, D. G., White, A. R., & Dando, S. J. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1355557 · Cited by 7
“• Upregulated by microglia in AD (Francistiová et al., 2020) and modulates chemokine production associated with CD8 + T cell recruitment in A β pathology • (Martin et al., 2019)Testing of a novel P2RX7 PET tracer ([11C]SMW139) in human post-mortem brain tissue demonstrated no differences in binding…”
Background
Metadata
- Authors
- Francistiová, L., Bianchi, C., Di Lauro, C., Sebastián-Serrano, Á., de Diego-García, L., Kobolák, J., Dinnyés, A., & Díaz-Hernández, M.
- Venue
- Frontiers in Molecular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2020-06-03
- Volume
- 13
- Pages
- 94-94
- ISSN
- 1662-5099 (ISSN-L)
- OpenAlex
- W3034089712
- Cited by
- 69
- References
- 80
- FWCI
- 5.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.